Merck and Mayo Clinic have entered a new R&D collaboration to integrate AI, multimodal clinical data, and advanced analytics into drug discovery and precision medicine development. Formed in February 2026, the agreement combines Mayo Clinic’s extensive clinical and genomic datasets with Merck’s investments in AI- and machine learning–enabled discovery technologies, including virtual cell modeling designed to improve disease characterization and early-stage development decisions.
Through the partnership, Merck will leverage the Mayo Clinic Platform, a secure research environment that aggregates de-identified clinical, molecular, imaging, and real-world healthcare data from Mayo’s U.S. operations and global partners. Using the Platform_Orchestrate program, Merck researchers will analyze laboratory results, imaging data, clinical documentation, and genomic information to validate AI models and refine biological hypotheses during discovery and preclinical development. The goal is to strengthen mechanistic understanding of disease and increase the likelihood that selected targets successfully translate into clinical trials.
The collaboration reflects a broader industry shift toward platform-based AI partnerships aimed at addressing persistent challenges in target identification and translational success. Rather than applying AI only to downstream analytics, Merck and Mayo plan to embed computational modeling early in the discovery workflow, enabling iterative feedback between clinical observations and experimental biology. Initial research efforts will focus on therapeutic areas such as inflammatory bowel disease, atopic dermatitis, and multiple sclerosis, where multimodal data integration may accelerate precision medicine strategies.
Executives from both organizations emphasized that aligning high-quality clinical data with AI-driven discovery tools could improve R&D productivity and bring therapies to patients more efficiently. As development costs rise and attrition remains high, partnerships that integrate real-world data platforms with AI-enabled modeling are increasingly viewed as essential to reducing risk and improving success rates across drug pipelines.
Click here for the original news story.